Cellbiotech to Launch Clinical Study of AD Treatment
Published: 2005-01-06 06:57:00
Updated: 2005-01-06 06:57:00
Cellbiotech Co., a domestic biotechnology venture company, announced on January 4th that it has launched a clinical study of its novel atopic dermatitis (AD) treatment using lactobacillus, which is commonly used for therapeutic purposes on intestinal disorders.
The clinical study will be cond...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
